88876-94-2|RSU 1164|1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol|-范德生物科技公司

RSU 1164

NMR下载 COA and HPLC MSDS下载
names：
1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol
CAS号：
88876-94-2
MDL Number：
MF(分子式)： C10H16N4O3 MW(分子量)： 240.26
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	1-(2,3-dimethylaziridin-1-yl)-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol
英文别名	RSU 1164; RSU-1164; RSU1164;
CAS号	88876-94-2
Inchi	InChI=1S/C10H16N4O3/c1-7-8(2)13(7)6-9(15)5-12-4-3-11-10(12)14(16)17/h3-4,7-9,15H,5-6H2,1-2H3
InchiKey	VKUQQJFQNDTATQ-UHFFFAOYSA-N
分子式 Formula	C10H16N4O3
分子量 Molecular Weight	240.26
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	RSU 1164(CAS:88876-94-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	RSU 1164 is an electron affinic agent that contain a nitro group together with a weakly basic alkylating aziridine moiety.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Siemann DW. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1115-8. PubMed PMID: 2703392.

[2]Henry JM, Isaacs JT. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy. J Urol. 1989 Jul;142(1):165-70. PubMed PMID: 2733098.

[3] Hofer KG, Lakkis M, Hofer MG. Cytocidal effects of misonidazole, Ro 03-8799, and RSU-1164 on euoxic and hypoxic BP-8 murine sarcoma cells at normal and elevated temperatures. Cancer. 1989 Apr 15;63(8):1501-8. PubMed PMID: 2924258.

[4] Deacon JM, Holliday SB, Ahmed I, Jenkins TC. Experimental pharmacokinetics of RSU-1069 and its analogues: high tumor/plasma ratios. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1087-90. PubMed PMID: 3755713.

[5] Walling J, Stratford IJ, Adams GE, Stephens MA. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069. Int J Radiat Biol Relat Stud Phys Chem Med. 1988 Apr;53(4):641-9. PubMed PMID: 3258298.

6: Walling JM, Deacon J, Holliday S, Stratford IJ. High uptake of RSU 1069 and its analogues melanotic melanomas. Cancer Chemother Pharmacol. 1989;24(1):28-32. PubMed PMID: 2541936.7: Roizin-Towle L, Pirro JP, Hall EJ. Studies with bifunctional bioreductive drugs. II. Cytotoxicity assayed with A-549 lung carcinoma cells of human origin. Radiat Res. 1990 Oct;124(1 Suppl):S50-5. PubMed PMID: 2236511.8: Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res. 1990 Oct;124(1 Suppl):S38-43. PubMed PMID: 2236508.9: Hei TK, He ZY, Piao CQ, Hall EJ. Studies with bifunctional bioreductive drugs. I. In vitro oncogenic transforming potential. Radiat Res. 1990 Oct;124(1 Suppl):S44-9. PubMed PMID: 2236509.10: Siemann DW. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. Br J Cancer. 1990 Sep;62(3):348-53. PubMed PMID: 2206941; PubMed Central PMCID: PMC1971466.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开